title: B-lymphocyte therapy for Type 2 diabetes: the 'B' side of diabetic medication?
authors.forename: Shane T
authors.initials: ST
authors.lastname: Grey
mesh_terms: D017667:Adipocytes / Q000276:immunology*; D054392:Adipokines / Q000276:immunology*; D000818:Animals; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use; D001402:B-Lymphocytes / Q000276:immunology*; D002450:Cell Communication; D002986:Clinical Trials as Topic; D003924:Diabetes Mellitus, Type 2 / Q000276:immunology / Q000628:therapy*; D006706:Homeostasis / Q000276:immunology; D006801:Humans; D007165:Immunosuppression Therapy; D008212:Lymphocyte Depletion / Q000379:methods*; D008264:Macrophages / Q000276:immunology*; D000069283:Rituximab; D016896:Treatment Outcome
chemical_list: D054392:Adipokines; D061067:Antibodies, Monoclonal, Humanized; D058846:Antibodies, Monoclonal, Murine-Derived; D000069283:Rituximab; C511911:belimumab